INFLIXIMAB TREATMENT FOR CHECKPOINT INHIBITOR INDUCED COLITIS: CLINICAL OUTCOMES FROM A MULTI-CENTRE STUDY

被引：0
|
作者：
Alexander, James L.
Sheth, Bhavisha
Ibraheim, Hajir
Little, Jessica
Khan, Muhammad S.
Richards, Camellia
Hunter, Nikki
Mchugh, Kathleen
Ratnakumaran, Raguprakash
Nathan, Paul
Choy, Julia
Crusz, Shanthini M.
Furness, Andrew
Turajlic, Samra
Pickering, Lisa
Larkin, James
Pinato, David
Papa, Sophie
Speight, Ally
Sharma, Anand
Powell, Nick
机构：
来源：
GASTROENTEROLOGY | 2021年 / 160卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
108
引用
收藏
页码：S26 / S27
页数：2
相关论文
共 50 条
  • [1] A MULTI-CENTRE STUDY OF INFLIXIMAB TREATMENT FOR CORTICOSTEROID-REFRACTORY CHECKPOINT INHIBITOR INDUCED ENTEROCOLITIS
    Alexander, James
    Ibraheim, Hajir
    Sheth, Bhavisha
    Pinato, David
    Teare, Julian
    Speight, Ally
    Papa, Sophie
    Sharma, Anand
    Crusz, Shanthini
    Powell, Nick
    GUT, 2021, 70 : A22 - A22
  • [2] Outcomes of Vedolizumab Treatment in Patients With Immune Checkpoint Inhibitor-Induced Diarrhea and Colitis: A Multi-Center Study
    Abu-Sbeih, Hamzah
    Ali, Faisal S.
    Alsaadi, Dana
    Jennings, Joseph
    Luo, Wenyi
    Gong, Zimu
    Richards, David
    Charabaty, Aline
    Wang, Yinghong
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S58 - S58
  • [3] INCIDENCE OF IMMUNE CHECK POINT INHIBITOR INDUCED DIARRHOEA/COLITIS-EXPERIENCE FROM A MULTI-CENTRE COHORT
    Spain, Lavinia
    Samani, Amit
    Ibraheim, Hajir
    Au, Lewis
    Tippu, Zayd
    Zhang, Shuai
    Merrick, Sophie
    Josephs, Debra
    Fazal, Waqas
    Papa, Sophie
    Powell, Nick
    Yousaf, Nadia
    Larkin, James
    Gore, Martin
    Turajlic, Samra
    GUT, 2018, 67 : A65 - A65
  • [4] Infliximab Versus Vedolizumab in Outpatient Treatment of Immune Checkpoint Inhibitor Colitis
    Joseph, Joel A.
    Townsend, Matthew J.
    Somappa, Aakash K.
    Sack, Jordan
    Leboeuf, Nicole R.
    Sharon, Elad
    Grover, Shilpa
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S164 - S165
  • [5] Clinical outcomes of endoscopically confirmed immune checkpoint inhibitor-induced colitis: A multicentre retrospective study
    Ibraheim, H.
    D'arienzo, P.
    Dean, N. J.
    Aboulela, M.
    Anderson, K.
    Manickavasagar, T.
    Vadera, S.
    Symington, J.
    Mullings, S.
    Olsson-brown, A.
    Young, K.
    Powell, N.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i911 - i911
  • [6] Clinical features of ulcerative colitis patients in Sardinia, Italy - First results from a multi-centre study
    Mocci, G.
    Demurtas, M.
    Onidi, F. M.
    Manca, R.
    Miculan, F.
    Dore, M. P.
    Colosso, B. Quarta
    Cicu, A.
    Cugia, L.
    Pisanu, R.
    Carta, M.
    Binaghi, L.
    Dore, M. F.
    Usai, P.
    Lai, M. A.
    Magri, S.
    Porcedda, M. L.
    Argiolas, M.
    Cabras, F.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S526 - S527
  • [7] A 'real-world' retrospective multi-centre study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis
    Kronsten, V.
    Colwill, M.
    Nayeemuddin, S.
    Limdi, J.
    Selinger, C.
    Scott, G.
    Al-Hillawi, L.
    Salehi, S.
    Blaker, P.
    Chung-Faye, G.
    Kent, A.
    Dubois, P.
    Hayee, B.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S480 - S480
  • [8] INFLIXIMAB INDUCTION REGIMES IN STEROID REFRACTORY ACUTE SEVERE COLITIS: MULTI-CENTRE STUDY WITH PROPENSITY SCORE ANALYSIS
    Sebastian, Shaji
    Myers, Sally
    Subramanian, Sreedhar
    GUT, 2019, 68 : A65 - A66
  • [9] Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis
    Dahl, Emilie Kristine
    Abed, Osama Karim
    Kjeldsen, Jens
    Donia, Marco
    Svane, Inge Marie
    Dige, Anders
    Agnholt, Jorgen Steen
    Bjerrum, Jacob Tveiten
    Seidelin, Jakob Benedict
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (09) : 1370 - 1382
  • [10] Editorial: Safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis
    Hanauer, Stephen
    Wang, Yinghong
    Shatila, Malek
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (01) : 150 - 151
12345